Crucial role for the VWF A1 domain in binding to type IV collagen

Blood

Volumn 125, Issue 14, 2015, Pages 2297-2304

  Flood, Veronica H ^a,b   Schlauderaff, Abraham C ^a,b,c   Haberichter, Sandra L ^a,b,c   Slobodianuk, Tricia L ^c   Jacobi, Paula M ^c   Bellissimo, Daniel B ^c   Christopherson, Pamela A ^c   Friedman, Kenneth D ^c   Gill, Joan Cox ^a,b,c   Hoffmann, Raymond G ^a   Montgomery, Robert R ^a,b,c   Abshire, T ^d   Dunn, A ^d   Bennett, C ^d   Lusher, J ^e   Rajpurkar, M ^e   Brown, D ^f   Shapiro, A ^g   Lentz, S ^h   Gill, J ⁱ   Leissinger, C ^j   Ragni, M ^k   Hord, J ^l   Manco Johnson, M ^m   Strouse, J ⁿ   Ma, A ^o   Valentino, L ^p   Boggio, L ^p   Sharathkumar, A ^q   Gruppo, R ^r   Kerlin, B ^s   Journeycake, J ^t   Kulkarni, R ^u   Green, D ^v   Mahoney, D ^w   Mathias, L ^x   Bedros, A ^x   Diamond, C ^y   Neff, A ^z   Di Michele, D ^aa   Giardina, P ^aa   Cohen, A ^ab   Paidas, M ^ac   Werner, E ^ad   Matsunaga, A ^ae   Tarantino, M ^af   Shafer, F ^ag   Konkle, B ^ah   Cuker, A ^ah   Kouides, P ^ai   Stein, D ^aj   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^c BLOOD RESEARCH INSTITUTE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ Comprehensive Center for Bleeding Disorders ^*  (United States)

^j TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^k UNIVERSITY OF PITTSBURGH   (United States)

^l AKRON CHILDREN'S HOSPITAL   (United States)

^m Mountain States Regional Hemophilia and Thrombosis Center   (United States)

ⁿ JOHNS HOPKINS CHILDREN S CENTER   (United States)

^o UNIVERSITY OF NORTH CAROLINA   (United States)

^p RUSH UNIVERSITY   (United States)

^q CHILDREN'S MEMORIAL HOSPITAL   (United States)

^r CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^s NATIONWIDE CHILDREN S HOSPITAL   (United States)

^t UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^u MICHIGAN STATE UNIVERSITY   (United States)

^v NORTHWESTERN UNIVERSITY   (United States)

^w BAYLOR COLLEGE OF MEDICINE   (United States)

^x LOMA LINDA UNIVERSITY   (United States)

^y UNIVERSITY OF WISCONSIN MADISON   (United States)

^z VANDERBILT UNIVERSITY   (United States)

^aa WEILL CORNELL MEDICAL COLLEGE   (United States)

^ab NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^ac YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ad CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

^ae CHILDREN S HOSPITAL OAKLAND   (United States)

^af College of Medicine ^*  (United States)

^ag DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^ah UNIVERSITY OF PENNSYLVANIA   (United States)

^ai ROCHESTER GENERAL HOSPITAL   (United States)

^aj Toledo Children's Hospital   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; RECOMBINANT VON WILLEBRAND FACTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR A1; PROTEIN BINDING;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; BLOOD CLOTTING; BLOOD GROUP TYPING; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SEQUENCE; HEMOSTASIS; HUMAN; HYDRODYNAMICS BASED TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; THROMBOCYTE; ANIMAL; CASE CONTROL STUDY; CELL CULTURE; CHEMISTRY; FLOW CYTOMETRY; GENETICS; METABOLISM; MUTATION; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION; VON WILLEBRAND DISEASE;

ANIMALS; BINDING SITES; CASE-CONTROL STUDIES; CELLS, CULTURED; COLLAGEN TYPE IV; FLOW CYTOMETRY; HUMANS; MICE; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84926664083     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-11-610824     Document Type: Article

References (35)

1. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977;60(2):390-404.
2. Mohri H, Fujimura Y, Shima M, et al. Structure of the von Willebrand factor domain interacting with glycoprotein Ib. J Biol Chem. 1988;263(34):17901-17904.
3. Pareti FI, Niiya K, McPherson JM, Ruggeri ZM. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem. 1987;262(28):13835-13841.
4. Ribba AS, Loisel I, Lavergne JM, et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost. 2001;86(3):848-854.
5. Riddell AF, Gomez K, Millar CM, et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood. 2009;114(16):3489-3496.
6. Flood VH, Lederman CA, Wren JS, et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF: CB in diagnosis of VWD. J Thromb Haemost. 2010;8(6):1431-1433.
7. Flood VH, Gill JC, Christopherson PA, et al. Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost. 2012;10(7):1417-1424.
8. Bornstein P, Sage H. Structurally distinct collagen types. Annu Rev Biochem. 1980;49:957-1003.
9. Saelman EU, Nieuwenhuis HK, Hese KM, et al. Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood. 1994;83(5):1244-1250.
10. Henrita van Zanten G, Saelman EU, Schut-Hese KM, et al. Platelet adhesion to collagen type IV under flow conditions. Blood. 1996;88(10):3862-3871.
11. Gould DB, Phalan FC, van Mil SE, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med. 2006;354(14):1489-1496.
12. Jeanne M, Labelle-Dumais C, Jorgensen J, et al. COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke. Am J Hum Genet. 2012;90(1):91-101.
13. Weng YC, Sonni A, Labelle-Dumais C, et al. COL4A1 mutations in patients with sporadic lateonset intracerebral hemorrhage. Ann Neurol. 2012;71(4):470-477.
14. Gould DB, Phalan FC, Breedveld GJ, et al. Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. Science. 2005;308(5725):1167-1171.
15. Howard MA, Sawers RJ, Firkin BG. Ristocetin: a means of differentiating von Willebrand's disease into two groups. Blood. 1973;41(5):687-690.
16. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res. 1986;43(3):303-311.
17. Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost. 2010;104(5):1009-1021.
18. Flood VH, Gill JC, Morateck PA, et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010;116(2):280-286.
19. Bellissimo DB, Christopherson PA, Flood VH, et al. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood. 2012;119(9):2135-2140.
20. Rodeghiero F, Tosetto A, Abshire T, et al; ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063-2065.
21. Flood VH, Gill JC, Christopherson PA, et al. Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. J Thromb Haemost. 2012;10(7):1425-1432.
22. Flood VH, Gill JC, Friedman KD, et al; Zimmerman Program Investigators. Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin Chem. 2013;59(4):684-691.
23. Pruss CM, Golder M, Bryant A, Hegadorn C, Haberichter S, Lillicrap D. Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W. J Thromb Haemost. 2012;10(5):940-950.
24. Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR. Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost. 2012;10(8):1646-1652.
25. Philipose S, Konya V, Sreckovic I, et al. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol. 2010;30(12):2416-2423.
26. Sadler JE, Ginsburg D; For the Consortium on von Willebrand Factor Mutations and Polymorphisms and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. A database of polymorphisms in the von Willebrand factor gene and pseudogene. Thromb Haemost. 1993;69(2):185-191.
27. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691-1695.
28. Ribba AN, Hilbert L, Lavergne JM, et al. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor. Blood. 2001;97(4):952-959.
29. Favaloro EJ. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost. 2009;35(1):60-75.
30. Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem. 1998;273(17):10396-10401.
31. Mancuso DJ, Kroner PA, Christopherson PA, Vokac EA, Gill JC, Montgomery RR. Type 2M: Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets. Blood. 1996;88(7):2559-2568.
32. Larsen DM, Haberichter SL, Gill JC, Shapiro AD, Flood VH. Variability in platelet- and collagenbinding defects in type 2M von Willebrand disease. Haemophilia. 2013;19(4):590-594.
33. Castaman G, Federici AB, Tosetto A, et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost. 2012;10(4):632-638.
34. Bonnefoy A, Romijn RA, Vandervoort PA, VAN Rompaey I, Vermylen J, Hoylaerts MF. von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen. J Thromb Haemost. 2006;4(10):2151-2161.
35. Keeling D, Beavis J, Marr R, Sukhu K, Bignell P. A family with type 2M VWD with normal VWF: RCo but reduced VWF: CB and a M1761K mutation in the A3 domain. Haemophilia. 2012;18(1):e33-2516. 2011.02676.x. Epub 2011 Oct. 17.